SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as community members rally around the OG meme coin, highlighting its strong community and potential for rebuilding meme culture. Talk centers on bullish sentiment, the importance of community, and the potential for significant growth, with some referencing a possible bottom in the crypto market.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending due to upcoming Phase 3 data being presented at a conference, sparking discussions of a potential short squeeze and comparisons to other high-flying stocks with similar ownership structures. Community members are highlighting the company's low share float, high institutional ownership, and the potential for buyout interest. Some caution is being urged due to the company's history and potential dilution.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors discuss its potential to join the trillion-dollar market cap club amid positive analyst outlooks and expected sales growth. Community members are weighing in on AI's impact, the health of the market, and potential opportunities for AMD in comparison to competitors. Semiconductor supply chain developments and potential impacts of trade policies are also being closely monitored.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom ($ZM) is trending as investors anticipate the Q3 earnings report and strategic moves, especially in AI, with analysts pointing to potential upside. The community is actively discussing whether Zoom's partnerships with Oracle and NVIDIA will drive enterprise adoption amid modest revenue growth guidance. Mixed sentiment exists, with some traders betting on a post-earnings surge, while others foresee a continued flatlining or even a decline.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

mF International ($MFI) is trending due to a recently announced $500M private placement to launch a digital asset treasury strategy, sparking both excitement and skepticism among investors. Some community members speculate about the company becoming a major crypto player, drawing comparisons to MicroStrategy ($MSTR) and highlighting the involvement of figures from the crypto world, while others worry about potential dilution and a pump-and-dump scheme.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amidst community discussion around its valuation and future prospects in the quantum computing sector. While some express optimism regarding long-term potential and technological advancements, others highlight concerns about revenue, profitability, and insider selling. Community members are actively debating the stock's fair value and potential catalysts.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending due to recent FDA updates on its biosimilar pipeline, specifically a complete response letter for AVT05 and approval in the European Economic Area for AVT03. The community is actively debating the implications of these regulatory decisions on the company's revenue outlook and potential market share, along with speculation about market manipulation.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members promote the memecoin and its association with cannabis culture on the Solana blockchain. The coin is being touted as 'like Bitcoin but way higher' with users sharing links to the project's website and social media.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is trending as community members highlight its strong community, potential for growth, and recent listing on MEXC. The crypto is being discussed for its association with the Solana ecosystem and potential as more than just a meme coin. Chatter includes speculation around upcoming announcements and a potential breakout.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

BMY is trending due to discussions around potential acquisitions and strong options activity, with traders highlighting significant profit potential on call options. Community members are speculating about BMY's next strategic move in the pharmaceutical landscape, particularly in areas like oncology and immunology, as well as potential mergers with other companies. Despite some generic competition challenges, the stock is being viewed as a value play with a high dividend yield, especially with discussions around strong revenue growth in Q2.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Bayer said its new Phase III stroke study of asundexian hit both primary efficacy and safety goals.</li><li>The update comes two years after the company halted the OCEANIC-AF trial when interim data showed asundexian was inferior to Eliquis.</li><li>The study enrolled more than 12,300 patients worldwide, and Bayer plans to engage with regulators as it prepares marketing submissions.</li></ul><p>Retail traders turned hyper bullish on Sunday after Bayer AG confirmed that its Phase III stroke study of asundexian met its primary efficacy and safety endpoints, two years after the company halted its separate OCEANIC-AF trial in 2023.&nbsp;</p><h2 class="st-heading-2"><strong>Asundexian Reduces Ischemic Stroke Risk&nbsp;</strong></h2><p>Bayer said patients taking 50 mg of asundexian once a day alongside antiplatelet therapy saw a meaningful drop in ischemic stroke risk compared with those given a placebo and antiplatelet therapy. The company added that the treatment did not lead to higher rates of major bleeding. Bayer said this is the first late-stage study of a drug in the Factor Xla inhibitor class, which helps prevent clots from forming, to be successfully completed.</p><h2 class="st-heading-2"><strong>Large Global Phase III Study&nbsp;</strong></h2><p>Bayer said the trial was&nbsp;conducted across multiple countries and medical centers, using a randomized, placebo-controlled design. More than 12,300 patients took part, all of whom had recently experienced a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The study tested whether adding asundexian to standard antiplatelet therapy could lower their chances of having another stroke.</p><h2 class="st-heading-2"><strong>High Burden Of Recurrent Strokes</strong></h2><p>The company noted the growing global need for better secondary stroke prevention. They said nearly 12 million people worldwide experience a stroke each year, and that 20%–30% are recurrent. One in five stroke survivors will have another stroke within five years, and recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk.</p><p>Mike Sharma, MD, principal investigator of OCEANIC-STROKE, said the topline results indicate that asundexian may become a new treatment option for reducing recurrent stroke risk.&nbsp;</p><h2 class="st-heading-2"><strong>Regulatory Path&nbsp;</strong></h2><p>Bayer said it will now engage with health authorities globally as it prepares to submit marketing authorization applications. Asundexian has Fast Track Designation from the U.S. Food and Drug Administration for stroke prevention in patients after a non-cardioembolic ischemic stroke. Bayer said asundexian remains investigational and is not approved in any country.</p><h2 class="st-heading-2"><strong>Halt Of OCEANIC-AF After Inferiority To Eliquis</strong></h2><p>Asundexian drew attention in 2023 when Bayer halted its OCEANIC-AF Phase III trial. Interim findings showed the drug did not perform as well as Eliquis, made by Bristol-Myers Squibb and Pfizer, in preventing strokes in high-risk atrial fibrillation patients. Bayer said the safety profile matched earlier studies and noted that independent trial supervisors advised continuing the stroke-focused OCEANIC-STROKE study.</p><p>Bayer said asundexian is part of the factor XI inhibitor drug class, which has also drawn interest from Novartis working with Blackstone, and from Bristol-Myers Squibb working with Johnson &amp; Johnson. The compound had been positioned as one of four new drug hopefuls Bayer said carried a combined peak sales potential of more than 12 billion euros. The program followed the company’s Xarelto blood thinner franchise, which is expected to lose protection from key European patents in 2026.</p><h2 class="st-heading-2"><strong>Stocktwits Mood Turns ‘Extremely Bullish’</strong></h2><p>On Stocktwits, retail sentiment for Bayer was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:970/142;" src="https://news.stocktwits-cdn.com/bayer_ss_png_e2cb5716df.webp" alt="bayer ss.png" width="970" height="142"><figcaption>BAYRY sentiment and message volume as of November 23 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/BAYRY">Bayer’s U.S.-listed stock</a> has risen 63% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Signage and the building of the Bayer AG pharmaceutical and biotechnology company are seen at one of its industrial sites in Wuppertal, North Rhine-Westphalia, Germany. (Photo by Michael Nguyen/NurPhoto via Getty Images)

Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt

The update comes two years after the company halted the OCEANIC-AF trial when interim data showed asundexian was inferior to Eliquis.

Equity

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth

Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.

REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD

Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion. 



BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU 

Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms

RHHBY Reports Positive Phase III Data on Breast Cancer Drug 

Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.

Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains 

Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.



Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales 

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.

Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?

Here is how Medpace (MEDP) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase 

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand. 

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Current Price	$7.94
Prev Close	$7.68
Open	$7.90
Dividend Yield	0.46%
50-Day Moving Average	$7.98
Beta	0.44
Avg. Volume	415,151.22
PE Ratio	-91.47

52-Week High	$8.70
52-Week Low	$4.79
Market Capitalization	$31.2B
EPS (Annual)	-$0.7025
Price to Book	0.90
Revenue Per Employee	$543,158.75
Enterprise Value/EBITDA	N/A

BAYRY
Bayer AG (ADR)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BAYRY News

BAYRYBayer AG (ADR)